Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia

Leukemia
Richard F SchlenkAML Study Group Ulm

Abstract

The purpose of our study was (i) to evaluate the impact of all-trans retinoic acid (ATRA) given as adjunct to chemotherapy and (ii) to compare second consolidation vs maintenance therapy in elderly patients with acute myeloid leukemia (AML). A total of 242 patients aged >or=61 years (median, 66.6 years) with AML were randomly assigned to ATRA beginning on day +3 after the initiation of chemotherapy (ATRA-arm, n=122) or no ATRA (standard-arm, n=120) in combination with induction and first consolidation therapy. A total of 61 patients in complete remission (CR) were randomly assigned to second intense consolidation (n=31) or 1-year oral maintenance therapy (n=30). After induction therapy the intention-to-treat analysis revealed a significant difference in CR rates between the ATRA- and the standard-arm (52 vs 39%; P=0.05). Event-free (EFS) and overall survival (OS) were significantly better in the ATRA-compared to the standard-arm (P=0.03 and 0.01, respectively). OS after second randomization was significantly better for patients assigned to intensive consolidation therapy (P<0.001). The multivariate model for survival revealed lactate dehydrogenase, cytogenetic risk group, age, and first and second randomization as prognostic va...Continue Reading

References

May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM J Keating
Jan 1, 1995·Cytogenetics and Cell Genetics·M HöglundN Mandahl
Sep 1, 1994·British Journal of Haematology·Z T MaungA G Hall

❮ Previous
Next ❯

Citations

Jan 30, 2008·International Journal of Hematology·Akira HorikoshiShigemasa Sawada
Jul 14, 2012·International Journal of Hematology·Masamitsu Yanada, Tomoki Naoe
Mar 30, 2011·Leukemia·K Theilgaard-MönchL Bullinger
May 27, 2009·Current Opinion in Hematology·Richard F Schlenk, Konstanze Döhner
May 27, 2009·Current Opinion in Hematology·Kevin PetrieSamuel Waxman
Aug 1, 1976·Australian and New Zealand Journal of Medicine·F R BühlerF J Koller
Oct 13, 2009·Clinical Chemistry and Laboratory Medicine : CCLM·Ulrike BacherTorsten Haferlach
Jan 14, 2005·International Journal of Hematology·Adolfo A Ferrando, A Thomas Look
May 23, 2014·Clinical Interventions in Aging·Ming Y Lim, Katarzyna Jamieson
Jun 15, 2006·Der Internist·W HiddemannT Büchner
Dec 2, 2015·Nature Reviews. Clinical Oncology·Catherine C CoombsRoss L Levine
Aug 5, 2009·Critical Reviews in Clinical Laboratory Sciences·Elzbieta Gocek, George P Studzinski
Nov 14, 2013·Expert Review of Hematology·Alessandro IsidoriGiuseppe Visani
Apr 2, 2009·Expert Opinion on Investigational Drugs·Camilla StapnesØystein Bruserud
Oct 17, 2008·Expert Opinion on Investigational Drugs·Anita RyningenOystein Bruserud
Feb 19, 2010·Expert Opinion on Pharmacotherapy·Felicetto Ferrara
Jan 30, 2015·Blood Reviews·Daniel E Johnson, Robert L Redner
Dec 7, 2010·Best Practice & Research. Clinical Haematology·Harry P Erba
Dec 7, 2010·Best Practice & Research. Clinical Haematology·Richard M Stone
Oct 28, 2008·Cancer Treatment Reviews·Andrea Kuendgen, Ulrich Germing
Aug 12, 2008·Seminars in Oncology·Verena Gaidzik, Konstanze Döhner
Aug 12, 2008·Seminars in Oncology·Hervé DombretClaude Gardin
Jul 10, 2008·Journal of Cellular Biochemistry·Michael LübbertH Phillip Koeffler
Jan 6, 2006·International Journal of Cancer. Journal International Du Cancer·Hagar SharabaniMichael Danilenko
Feb 15, 2011·British Journal of Haematology·Daniel A PollyeaBruno C Medeiros
Oct 7, 2005·Critical Reviews in Oncology/hematology·W HiddemannUNKNOWN German AML Cooperative Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.